Mark Gardner was named President of GeneDx Holdings Corp., effective June 15, 2026. As of November 15, 2026, GeneDx Holdings Corp. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 16, 2026, naming 1 appointment (Form 8-K, June 16, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like GeneDx Holdings Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
GeneDx Holdings Corp. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as GeneDx Holdings Corp. files it.
Also on the record for GeneDx Holdings Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 6.42% of the class | 5%+ stakes | Source |
| November 6, 2026 | Stake report, Schedule 13G, by WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 5.2% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by THE GOLDMAN SACHS GROUP, INC. | 5.8% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 5.33% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| May 22, 2026 | Stake report, Schedule 13D/A, by CMLS Holdings LLC | 17.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13D/A, by CMLS HOLDINGS LLC | 17.9% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13D/A, by CMLS HOLDINGS LLC | 16.7% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 4.3% of the class | 5%+ stakes | Source |
| August 26, 2025 | Stake report, Schedule 13D/A, by CMLS Holdings LLC | 12.5% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Summit Partners Public Asset Management, LLC | 3.04% of the class | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 0.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs GeneDx Holdings Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on GeneDx Holdings Corp. and the records around it.
GeneDx Holdings Corp. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Summit Partners Public Asset Management, LLC also filed stake reports on 1 other company: SOLARIS ENERGY INFRASTRUCTURE, INC. (Nov 2025)
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC also filed stake reports on 21 other companies: Baldwin Insurance Group, Inc. (Nov 2026), i3 Verticals, Inc. (Aug 2026), Revolve Group, Inc. (Aug 2026)
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
Watch GeneDx Holdings Corp.
Get an email when GeneDx Holdings Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on GeneDx Holdings Corp.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on GeneDx Holdings Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GeneDx Holdings Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-16 | In | President | 2026-06-15 | 8-K, 2026-06-16 |
Who leads GeneDx Holdings Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Mark Gardner, appointed, effective 2026-06-15 (filed 2026-06-16).
New leaders reset buying decisions — get the Full Report on GeneDx Holdings Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at GeneDx Holdings Corp., with the record behind each one.
Find candidates like President at GeneDx Holdings Corp.Every change, in the filing's words
Appointed: Mark Gardner, President, effective 2026-06-15
On June 16, 2026, GeneDx Holdings Corp. (the "Company") announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.
- As President, Mr. Gardner will oversee the Company's lab and commercial operations.
- Mr. Gardner will report to Katherine Stueland, Chief Executive Officer of the Company, and will serve on the Company's executive leadership team.
- Prior to joining the Company, Mr. Gardner served as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics Incorporated, from September 2022 to June 2026.
- Mr. Gardner also held executive leadership roles at prominent diagnostic and life sciences companies, including at Corza Medical Inc., where he was Executive Partner, Senior Vice President and General Manager of European Commercial Operations and Biosurgery Products from June 2019 to October 2022, at OmniSeq Corporation, where he was Chief Executive Officer, and at Thermo Fisher Scientific Inc., where he held Vice President and General Manager positions.
- Mr. Gardner holds a B.S. in History from the United States Naval Academy, an M.A. in National Security Studies from Georgetown University, and an M.B.A. from The Wharton School of the University of Pennsylvania.
- The employment agreement provides for an initial term of three years and automatically renews for successive one-year terms unless earlier terminated.
Tools for this story
Each opens in a new tab, filled in for GeneDx Holdings Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
